髋膝关节置换术后死亡风险随时间如何变化?
基于澳大利亚骨科协会国家关节置换登记系统2003至2016年243057例全髋和363355例全膝置换数据,按年龄、性别和日历年校正后计算标准化死亡比。全髋和全膝置换术后早期死亡率低于预期,但该趋势随时间减弱,12年后死亡率高于预期。
要点
- 全髋置换术后1年标准化死亡比0.50,第13年升至1.07。
- 全膝置换术后1年标准化死亡比0.39,第13年升至1.09。
- 术后8至9年内死亡率低于预期,12年后高于预期。
核心结论
- 全髋和全膝置换术后前8至9年死亡率低于基于人群标准的预期值,但随时间逐渐升高,12年后高于预期。
- 术后早期死亡率低于预期可能源于患者选择,即接受初次置换的患者手术时健康状况优于同龄同性别匹配人群。
- 晚期死亡率高于预期不能以回归均值解释,因已超出均值。
- 了解是否存在可改变因素与死亡率升高相关很重要,原因尚不确定。
研究设计与样本
- 基于澳大利亚骨科协会国家关节置换登记系统2003至2016年因骨关节炎行初次全髋置换243057例和全膝置换363355例的数据,结合澳大利亚统计局生命表,分别计算髋和膝的标准化死亡比、相对死亡率和超额死亡率。
- 随访自手术日至13年,平均5.8年。
- 证据等级为III级,治疗性研究。
主要发现
- 全髋置换超额死亡率(每千人)从术后1年减少11例死亡(95%CI,减少10至11例)增至第13年增加4例死亡(95%CI,增加0至9例),标准化死亡比从0.50(95%CI,0.48-0.52)升至1.07(95%CI,0.99-1.14)。
- 全膝置换超额死亡率(每千人)从术后1年减少12例死亡(95%CI,减少12至13例)增至第13年增加5例死亡(95%CI,增加2至9例),标准化死亡比从0.39(95%CI,0.37-0.40)升至1.09(95%CI,1.03-1.15)。
局限性
- 登记系统包含澳大利亚所有开展关节置换医院的近完全(98%-100%)数据,但不包括离开该国者的随访数据。
- 死亡风险变化的原因尚不确定。
- 未来研究需确定不同患者因素对晚期死亡率的影响,包括关节置换患者较高的肥胖率以及骨关节炎和/或其治疗与其他形式关节炎类似增加晚期死亡率的关联或因果影响。
- 关节置换装置本身也可能影响晚期死亡率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mortality after THA and TKA is lower than expected for several years after surgery when compared with age- and sex-adjusted population data. With long-term followup (beyond approximately 10 years), some evidence has suggested that this trend reverses, such that postsurgical mortality is higher than expected as more time passes. However, the degree to which this may be the case has not been clearly established. QUESTIONS/PURPOSES: In this large-registry study, we asked: What is the long-term mortality after THA and TKA compared with the expected mortality, adjusted for age, sex, and calendar year. METHODS: Using data on 243,057 THAs and 363,355 TKAs performed for osteoarthritis from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) from 2003 to 2016, and life tables from the Australian Bureau of Statistics the Standardised Mortality Ratio (SMR), relative mortality and excess mortality (relative to the expected mortality for people of the same sex and age in the same country) was calculated separately for hips and knees. The AOANJRR contains near-complete (98%-100%) data from all hospitals in Australia performing arthroplasty but does not include followup data on people who have left the country. Followup was from the date of surgery to 13 years, mean 5.8 years. RESULTS: We found a lower-than-expected mortality for THA and TKA in the early years after surgery. This association diminished over time and the mortality became higher than expected after 12 years for both THA and TKA. For THA, the excess mortality (per thousand people) increased from 11 fewer deaths (95% CI, 10-11 fewer) after 1 year to four more deaths (95% CI, 0-9 more) in the 13th year, and the SMR increased from 0.50 (95% CI, 0.48-0.52) after 1 year to 1.07 (95% CI, 0.99-1.14) in the 13th year. For TKA, the excess mortality (per thousand people) increased from 12 fewer deaths (95% CI, 12-13 fewer) after 1 year to five more deaths (95% CI 2-9 more) in the 13th year, and the SMR increased from 0.39 (95% CI, 0.37-0.40) after 1 year to 1.09 (95% CI, 1.03-1.15) in the 13th year. CONCLUSIONS: Mortality after hip and knee arthroplasty is lower than expected (based on population norms) in the first 8 years to 9 years but gradually increases over time, becoming higher than expected after 12 years. The lower-than-expected mortality in the early years after surgery is likely the result of patient selection with patients undergoing primary arthroplasty having better health at the time of surgery than that of the age- and sex-matched population. The increasing mortality over time cannot be regression to the mean, as late mortality is higher than expected, moving beyond the mean. It is important to understand if there are modifiable factors associated with this increased mortality. The reasons for the change are uncertain. Factors to consider in future research include determining the effect of different patient factors on late mortality. Some of these included higher obesity rates for joint replacement patients and the association or causal impact of osteoarthritis and/or its treatment to increase late mortality in a similar manner to other forms of arthritis. There is also a possibility that the arthroplasty device itself may affect late mortality. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Harris IA, Hatton A, Pratt N, et al. How Does Mortality Risk Change Over Time After Hip and Knee Arthroplasty? Clin Orthop Relat Res. 2019. PMID: 31136444. doi:10.1097/CORR.0000000000000673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。